Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography

Author(s): Mark Lubberink

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 38 , 2016

Become EABM
Become Reviewer
Call for Editor


P-glycoprotein function is associated with a number of neurodegenerative and psychiatric diseases as well as with pharmacoresistance to for example antiepileptic drugs. The ability to measure P-gp function in vivo would allow for an increased understanding of the mechanisms of disease and treatment. This review assesses the various approaches to in vivo quantification of P-gp function using currently available P-gp tracers and PET in humans. First, the use of compartment models, and their interpretation in terms of P-gp function at the blood-brain barrier, is discussed. Then, the methods that have been used to quantify PET data of the P-gp tracers [11C]verapamil, [11C]N-desmetyl-loperamide (dLop), [11C]laniquidar, [11C]phenytoin, [11C]tariquidar and [11C]elacridar are reviewed. In summary, the extraction of P-gp substrate PET tracers, which is their plasma to tissue rate constant K1 corrected for variations in regional cerebral blood flow, is generally considered to be the preferred measure of P-gp function.

Keywords: PET, P-glycoprotein, quantification, tracer kinetics, blood-brain barrier.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 29 November, 2016
Page: [5786 - 5792]
Pages: 7
DOI: 10.2174/1381612822666160804093852
Price: $65

Article Metrics

PDF: 27
PRC: 1